National Bank of Canada
EDIT icon

National Bank of Canada’s Editas Medicine EDIT Stock Holding History

National Bank of Canada’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.17K Sell
2,500
-541
-18% -$1.15K ﹤0.01% 2428
2025
Q4 		$6.23K Buy
3,041
+341
+13% +$984 ﹤0.01% 2400
2025
Q3 		$9.34K Sell
2,700
-281
-9% -$784 ﹤0.01% 2340
2025
Q2 		$6.53K Hold
2,981
– – ﹤0.01% 2440
2025
Q1 		$3.46K Hold
2,981
– – ﹤0.01% 2434
2024
Q4 		$3.79K Buy
2,981
+828
+38% +$2.11K ﹤0.01% 2485
2024
Q3 		$7.34K Sell
2,153
-927
-30% -$4.04K ﹤0.01% 2140
2024
Q2 		$14.2K Buy
3,080
+280
+10% +$1.58K ﹤0.01% 2050
2024
Q1 		$14.9K Buy
2,800
+500
+22% +$4.16K ﹤0.01% 2092
2023
Q4 		$22.9K Hold
2,300
– – ﹤0.01% 1984
2023
Q3 		$16.4K Buy
2,300
+240
+12% +$2.06K ﹤0.01% 2079
2023
Q2 		$17K Hold
2,060
– – ﹤0.01% 2048
2023
Q1 		$14.9K Hold
2,060
– – ﹤0.01% 2045
2022
Q4 		$18.3K Buy
+2,060
New +$22.6K ﹤0.01% 2027
2022
Q1 		– Sell
-140
Closed -$2.6K – 2894
2021
Q4 		$4K Buy
+140
New +$4.82K ﹤0.01% 2572

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

National Bank of Canada's EDIT Position: Q1 2026 in Review

National Bank of Canada reduced its Editas Medicine (EDIT) stake by 18% in Q1 2026, selling an estimated $1.15K and leaving 2,500 shares worth $6.17K. The position accounts for ﹤0.01% of the portfolio, ranked #2428.

National Bank of Canada first reported a position in EDIT in Q4 2021 and has held it in 15 quarters since. The position peaked at $22.9K in Q4 2023. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • National Bank of Canada held 2,500 shares of Editas Medicine worth $6.17K as of Q1 2026.
  • National Bank of Canada sold 541 Editas Medicine shares in Q1 2026, an estimated $1.15K.
  • Editas Medicine made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2428 holding.
  • National Bank of Canada first reported a position in Editas Medicine in Q4 2021 and has held it in 15 quarters since.
  • National Bank of Canada's Editas Medicine position peaked at $22.9K in Q4 2023.
  • 208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.